Jordan Kadish

News

05/12/2023

According to findings from a phase 3 trial, biosimilar rituximab had comparable efficacy and safety to originator rituximab among patients with diffuse large B-cell lymphoma.

According to findings from a...

05/12/2023

Oncology

News

Enasidenib Improved Overall Response Rates in Patients With Late-Stage Mutant-IDH2 R/R AML

02/27/2023

Jordan Kadish ;

A phase 3 study found that enasidenib yielded positive results in improving EFS and ORR rates among older patients with late-stage mutant-IDH2 relapsed/refractory AML.

A phase 3 study found that...

02/27/2023

Oncology

News

Idecabtagene Vicleucel Treatment Among Patients With R/R Multiple Myeloma

03/30/2023

Jordan Kadish ;

According to findings of a retrospective study, idecabtagene vicleucel treatment did not yield significantly higher levels of efficacy or safety among patients with R/R multiple myeloma, compared to results of a previous study.

According to findings of a...

03/30/2023

Oncology

News

Carfilzomib Plus R-ICE Regimen Well-Tolerated Among Patients With Relapsed/Refractory DLBCL

06/26/2023

Jordan Kadish ;

The addition of carfilzomib to the rituximab, ifosfamide, carboplatin, and etoposide treatment regimen was well-tolerated among patients with R/R DLBCL.

The addition of carfilzomib to...

06/26/2023

Oncology

News

Fludarabine-Based Treatment vs Standard Regimen Among Patients With WT1-Mutated AML

10/11/2023

Jordan Kadish ;

In a retrospective analysis, a fludarabine-based regimen showed improved relapse-free survival following allogeneic stem cell transplantation compared to a traditional regimen among patients with WT1-mutated acute myeloid leukemia.

In a retrospective analysis, a...

10/11/2023

Oncology

News

BTK Inhibitor Zanubrutinib vs Ibrutinib Among Patients With Waldenström Macroglobulinemia

09/27/2023

Jordan Kadish ;

BTK inhibitor zanubrutinib exhibited similar efficacy and improved safety compared to ibrutinib among patients with Waldenström macroglobulinemia, according to a final analysis of the phase 3 ASPEN trial.

BTK inhibitor zanubrutinib...

09/27/2023

Oncology

News

Venetoclax Plus Conditioning Regimen for Patients With AML and FLT3-ITD-Mutated Undergoing AlloHSCT

03/27/2023

Jordan Kadish ;

Venetoclax plus a conditioning regimen yielded high overall survival among patients with AML undergoing allogeneic hematopoietic stem cell transplantation, and the FLT3-ITD gene mutation was revealed to be present in 51.6% of patients.

Venetoclax plus a conditioning...

03/27/2023

Oncology

News

Sorafenib Maintenance Post-Transplantation Among Patients With FLT3-ITD Mutated AML

04/15/2023

Jordan Kadish ;

According to a phase 3 trial, sorafenib maintenance post-transplantation yielded safe results among patients with FLT3-ITD mutated AM undergoing allogeneic hematopoietic stem cell transplantation.

According to a phase 3 trial,...

04/15/2023

Oncology

News

Mini-Hyper CVD Chemotherapy Plus Inotuzumab Ozogamicin Regimen With or Without Blinatumomab Demonstrates Efficacy, Safety for R/R Pre-B ALL

07/06/2023

Jordan Kadish ;

Mini-hyper-CVD plus inotuzumab with or without blinatumomab showed efficacy in patients with relapsed/refractory pre-B ALL, with improved survival after the addition of blinatumomab, according to an updated analysis of a phase 2 trial.

Mini-hyper-CVD plus inotuzumab...

07/06/2023

Oncology

News

Spleen Volume Reduction Associated With Survival Benefit Among Patients With Myelofibrosis Receiving Pacritinib

12/05/2023

Jordan Kadish ;

According to a retrospective analysis of the PERSIST-2 trial, achieving spleen volume reduction predicted overall survival outcomes among patients with myelofibrosis receiving pacritinib, but not among those receiving current best available...

According to a retrospective...

12/05/2023

Oncology